Copyright(c) 2011 Eisai China lnc.All Rights Reserved.
沪ICP备11005394号-1
沪公网安备31010602001439号
Customer Service Hotline
021-62881220
LINKS
? Record information of Representative
? 已上市替普瑞酮胶囊铬限量检验报告公示说明
History
Eisai China Inc. is a pharmaceutical company wholly-owned by Eisai Co., Ltd. (Eisai), a Japanese multinational pharmaceutical company headquartered in Tokyo, with strong R&D capabilities. Eisai has been smoothly developing its business in China since the early 1990s, Eisai China, Inc. currently promotes more than 10 pharmaceutical brands in China, specializing in the Central Nervous System, Digestive System, Endocrine and Orthopedic areas.
CHAPTER 1
Shenyang Eisai, Business Initial（1991-1995）
1991 Shenyang Eisai Pharmaceutical Co., Ltd. was established. 1993 Production of NEQ tablet officially started in China. CHAPTER 2
Suzhou Eisai, Product Localization（1996-2001）
1996 Eisai(Suzhou)Pharmaceutical Co., Ltd. was established. 1997 Mecobalamin Injection and Neuqinon were launched in China. 1998 Eisai(Suzhou)Pharmaceutical Co., Ltd. obtained GMP certification. 1999 Production of Eisai Suzhou officially started in May, Merislon and Myonal were launched in China. CHAPTER 3
Eisai China Inc., Product Line Enrichment（2002-2014）
2002 Company Name was officially changed to Eisai China Inc. 2003-2006 Mecobalamin sugar-coated tablet, Aricept, Fareston, Pariet, Selbex, and Stronger Neo-Minophagen C were launched in China. 2009-2014 Eisai China Inc. established 9 branches in Beijing, Guangzhou, Chengdu, Xi’an, Shenyang, Hangzhou, Qingdao, Tianjin, and Fuzhou. 2010 Eisai (Suzhou) Trading Co., Ltd. was established. 2014 Mecobalamin film-coated tablet was launched in China. CHAPTER 4
Eisai China Holdings, Enterprise Group Development（2014-now）
2014 Eisai China Holdings Ltd. was established and China Region was set up.
Eisai China Inc. completed construction of new parenteral facility.2015 Eisai Liaoning Pharmaceutical Co., Ltd. was established; Eisai China entered the generic drug market in China. 2016 E-WAY 2025 , a 10-year mid -tern plan, was official launched. 2017 Eisai China Inc. completed construction of oral solid dose production facility. 2017 Aricept was approved for SAD indication in China; Stalevo and Comtan were introduced to China. 2018 Cidine and Lenvima were launched in China. 2019 Halaven and Fycompa were launched in China. 2020 Eisai China Region launched four new strategies.
Jingyi Weixiang (Shanghai) Health Industry Development Co. Ltd, a joint-venture company, was established.2021 “EWAY Future & Beyond” was started.
“Yin-Fa-Tong” obtained Internet Hospital License by Health Commission of Jing’an District of Shanghai.2022 DAYVIGO was launched in the Greater Bay Area.
hhceco Declaration was officially published.
Eisai’s business in HKSAR and MSAR officially transferred to Eisai China.
